Zevra Therapeutics (ZVRA) is a US-listed Healthcare company in Biotechnology with a market capitalization of $717M, trading at
2.13 on the NASDAQ. This SniperIQ fundamentals page covers Zevra Therapeutics's valuation (P/E 5.6x, P/B 3.4x), profitability (net margin 101.6%), revenue (
06M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$717M
P/E (TTM)5.6x
Net Margin101.6%
Revenue (FY25)
06M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Zevra Therapeutics's market cap?
Zevra Therapeutics (ZVRA) has a market capitalization of approximately $717M, trading at
2.13 on the NASDAQ. Market cap moves with the live share price.
What is Zevra Therapeutics's P/E ratio?
Zevra Therapeutics's trailing twelve-month P/E ratio is 5.6x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zevra Therapeutics?
Zevra Therapeutics runs a net profit margin of 101.6%, a gross margin of 85.5%, and an operating margin of -39.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zevra Therapeutics generate?
Zevra Therapeutics reported revenue of
06M for fiscal year 2025, with net income of $83M and earnings per share (EPS) of 1.4. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zevra Therapeutics pay a dividend?
Zevra Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Zevra Therapeutics financially healthy?
Zevra Therapeutics carries a debt-to-equity ratio of 0.01x and a current ratio of 4.89x, with a market beta of 0.85. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zevra Therapeutics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zevra Therapeutics (ZVRA) the key facts are: market cap $717M, P/E 5.6x, revenue
06M, 52-week range 7.16-15.035. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zevra Therapeutics's full fundamentals live
Get Zevra Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.